Anders Essen-Möller resigns as Chairman of the Board of Directors due to health reasons

April 19, 2024

NextCell Pharma AB ("NextCell" or the "Company") today announces that its long-time Chairman of the Board, Anders Essen-Möller, after ten years of dedicated leadership, will step down from his role on May 20th, 2024 due to health reasons. Anders has been a central figure in NextCell's journey since 2014 when the Company was founded by Diamyd Medical AB together with board members Hans-Peter Ekre and Edvard Smith, as well as CEO Mathias Svahn and Lena Wikingsson.

"Anders is a mentor and role model. His resignation will not mean a disconitation of our close relationship we have built up over the years. I look forward to continuing to seek his advice even after he has left his official role in the Company," says CEO Mathias Svahn.

Prior to Anders' departure, the board has actively started working on identifying a suitable replacement and has assigned the nomination committee, together with NextCell's management team, the task of presenting candidates for the position of chairman before the annual general meeting on November 28, 2024. During this transition period, Hans-Peter Ekre, one of NextCell's board members, will and co-founder, to act as acting chairman of the board until the board is full and a new regular chairman can be appointed.

"NextCell looks forward to an exciting future with continued growth, while we thank Anders for his contribution and wish him the best”, says Hans-Peter Ekre. “During the spring and summer, we will intensify contacts with attractive partners for T1D and also with distributors for the resale of stem and immunomodulating cells."

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company that is in phase 2 studies with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase 3 study. ProTrans is manufactured utilizing the patented platform technology for selection of optimal cells with potency to treat inflammatory disorders including autoimmune diseases. NextCell owns Cellaviva, the largest stem cell bank in the Nordics and QVance, a quality analysis CRO company in start up.

Download attachment Read full press release on Cision (external link)

2017-08-10

NextCell Pharmas first delivery of ProTrans™

NextCell Pharma AB (”NextCell”) today, received the first delivery of the drug candidate ProTrans™ from their manufacturer PBKM.

NextCell Pharma AB (”NextCell”) today, received the first delivery of the drug candidate ProTrans™ from their manufacturer PBKM....

Read more Read more

2017-08-08

Stem cell company NextCell Pharma receives approval from Ethics Committee

NextCell Pharma AB (NEXTCL) announced today that approval has been obtained from the Ethics Testing Board EPN, to develop assays from umbilical cord tissue. The collection is performed by regular staff at the clinic at Karolinska University Hospital in Huddinge. The project is conducted by Edvard Smith, Professor of Molecular Genetics at the Department of Laboratory Medicine at Karolinska Institutet, and one of the founders of the Company. The results may be included in the Company's proprietary intellectual property regarding ProTrans. ProTrans is developed for stem cell therapies for

Read more Read more

2017-07-31

NextCell Pharma updates on its current situation in its first quarterly report

NextCell Pharma AB (”NEXTCL”, “NextCell”) today, released its first quarterly report (April-June) since its introduction on Aktietorget. Following the issue in July, and after payment of study drug the Company has approximately SEK 20 million in cash, while the "burn rate" for the reporting period (April-June) was 3.5 MSEK (listing on Aktietorget occurred after the closing of this quarterly report). During the reporting period NextCell Pharma has recruited Leo Groenewegen, who took up the position of CFO. Besides his duties as CFO, Leo Groenewegen, together with Chairman Anders Essen-Moller,

Read more Read more

2017-07-24

NextCell Pharma AB submits clinical trial application for its drug candidate ProTrans™

NextCell Pharma AB ("NextCell") announced today that a clinical trial application for ProTrans™, a stem cell product developed with NextCell's Proprietary Selection Algorithm, has been submitted to the Medical Products Agency (Läkemedelsverket). The study is planned to evaluate the safety and efficacy of ProTrans™ in adult patients with type 1 diabetes diagnosed within two years. The study sponsor is NextCell and the principal investigator is Professor Per-Ola Carlsson, who works at Uppsala University and the Academic Hospital in Uppsala. The study will be conducted together with Karolinska

Read more Read more

2017-07-19

Disclosure notice: NextCell Pharma AB’s Chairman of the Board acquires additional shares

NextCell Pharma AB (”NextCell”) announces today, on July 19th 2017, that Chairman of the Board, Anders Essen-Möller, has acquired 263.020 shares in the company. Before the acquisition, Essen-Möller held 737.033 shares, equivalent to approximately 8.74 percent of the votes and capital. After the acquisition, Essen-Möller holds 1.000.053 shares, equivalent to approximately 11.76 percent of the votes and capital in NextCell.

Read more Read more

2017-07-13

First day of trading in stem cell company NextCell Pharma AB

NextCell Pharma AB (”NextCell”) announces today that trading with its shares and warrants of series TO 1 will commence today at the AktieTorget stock exchange. The shares will be traded under the name “NEXTCL” with the corresponding ISIN code SE009723125. The warrants will be designated with the name “NEXTCL TO 1” and ISIN code SE009888795. NextCell develops stem cell therapies, where stem cells from donated umbilical cords can treat patients who are not family of the donor. The cells are developed with NextCell's proprietary method and the company's first product, ProTrans™, is intended for

Read more Read more